

Clinical DIABETES®

PRACTICAL INFORMATION
FOR PRIMARY CARE

SPRING 2018 | VOLUME 36 | NUMBER 2



CONNECT WITH US

facebook.com/adajournals

twitter.com/ada_journals

On the cover: ©2018 Keith Negley c/o theispot.

FEATURE ARTICLES

- 100** A Culturally Tailored Community Health Worker Intervention Leads to Improvement in Patient-Centered Outcomes for Immigrant Patients With Type 2 Diabetes, *by Nadia S. Islam, Laura C. Wyatt, M.D. Taher, Lindsey Riley, S. Darius Tandon, Michael Tanner, B. Runi Mukherji, and Chau Trinh-Shevrin*
- 112** Does Time-in-Range Matter? Perspectives From People With Diabetes on the Success of Current Therapies and the Drivers of Improved Outcomes, *by Ava S. Runge, Lynn Kennedy, Adam S. Brown, Abigail E. Dove, Brian J. Levine, Sophie P. Koontz, Varun S. Iyengar, Sarah A. Odeh, Kelly L. Close, Irl B. Hirsch, and Richard Wood*
- 120** Using Shared Decision-Making to Address Possible Overtreatment in Patients at High Risk for Hypoglycemia: The Veterans Health Administration's Choosing Wisely Hypoglycemia Safety Initiative, *by Samantha M. Wright, Sandra C. Hedin, Mark McConnell, Brian V. Burke, Sharon A. Watts, Donna M. Leslie, David C. Aron, and Leonard M. Pogach*
- 128** The Effect of Elevated A1C on Immediate Postoperative Complications: A Prospective Observational Study, *by Pinxia Chen, Katherine K. Hallock, Christie L. Mulvey, Arthur S. Berg, and Verghese T. Chierian*
- 133** How Does Diabetes Affect Daily Life? A Beyond-A1C Perspective on Unmet Needs, *by Divya Gopisetty, Brian Levine, Nancy Liu, Phin Younge, Adam Brown, Kelly L. Close, and Richard Wood*
- 138** Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?, *by Vanita R. Aroda, Joseph R. Arulandu, and Anthony J. Cannon*
- 149** Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications, *by Carol H. Wysham, Carlos Campos, and Davida Kruger*
- 160** Health Care Providers' Perceptions of Responsibilities and Resources to Reduce Type 2 Diabetes Risk After Gestational Diabetes Mellitus, *by Sumali S. Hewage, Shweta R. Singh, Claudia Chi, Jerry K.Y. Chan, Tong Wei Yew, Wee Meng Han, and Joanne Yoong*
- 168** Endocrinologists' Opinions of Diabetology as a Primary Care Subspecialty, *by Amber M. Healy, Jay H. Shubrook, Frank L. Schwartz, Doyle M. Cummings, Almond J. Drake, III, and Robert J. Tanenberg*

- 174** Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know, *by Neil Skolnik, Debbie Hinnen, Yan Kiriakov, Melissa L. Magwire, and John R. White, Jr.*

DEPARTMENTS

92 ***Diabetes Is Primary***

Timely News and Notes for Primary Care Providers, *by Max Bingham*

97 ***Editorial***

There Are Great New Medications Out There—Why Aren't We Using Them?, *by Stephen Brunton, Editor-in-Chief*

184 ***Quality Improvement Success Stories***

Diabetes Center of Excellence Hypoglycemia Emergency Preparedness Project, *by Ellen C. Cobb, Nina A. Watson, Jana Wardian, Connie C. Morrow, and Tom J. Sauerwein*

Connecting the Dots: An Interdisciplinary Diabetes Quality Improvement Initiative, *by Rachel Waller, Deborah Koehn, Susan Miller, Linda Thurby-Hay, and Trang Le*

Internal Experts Collaborate to Reduce Critical Hypoglycemia and Insulin Errors and Improve Insulin Administration Timing, *by Kelley Szalc and Linda Nicolaus*

The Discharge Companion Pilot Program, *by Jennifer Bingham, Patrick Campbell, Sandra Leal, Ann M. Taylor, Kate Schussel, and Terri Warholak*

202 ***Patient Education***

Good to Know: Factors Affecting Blood Glucose

203 ***Clinical Pharmacology Update***

Freestyle Libre Glucose Monitoring System, *by Alyson Blum*

205 ***Case Studies***

Basaglar: A Hypersensitivity Reaction, *by Elizabeth M. Gavioli, Roman Fazylov, and Gulmira Sardo*

208 ***Erratum***

Delayed Response to U-500 Regular Insulin. *Clinical Diabetes* 2018;36:77–79. DOI: 10.2337/cd16-0058, *by Mayer B. Davidson*